A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout
A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout
This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.
This is a Phase 3, open-label, uncontrolled, extension study to assess the long-term efficacy and safety of lesinurad monotherapy in subjects who completed the double-blind treatment period in Study RDEA594-303.
Inclusion Criteria:
Exclusion Criteria:
Trumbill, Connecticut 06611, United States
Meridian, Indiana 83646, United States
Landsdale, Pennsylvania 19446, United States
Suffold, Virginia 23435, United States
Silverglen, Durban 4092, South Africa
Muckleneuk, Pretoria 0002, South Africa